Another phase 2 trial plans to include 96 patients aged 28 days to 18 years with relapsed AML or ALL (both B-ALL and T-ALL) and is currently ongoing, and patients will be treated with isatuximab, another monoclonal antibody against CD38 combined with chemotherapy (NCT03860844). The gene discussed is CD38; the disease is acute lymphoblastic leukemia.